伊马替尼联合造血干细胞移植或化疗治疗bcr-abl+急性淋巴细胞白血病

 目的　探讨伊马替尼联合异基因造血干细胞移植（allo-HSCT）或化疗治疗bcr-abl+融合基因成年人急性淋巴细胞白血病（ALL）（以下简称成年人ALL）的疗效。方法　12例成年人ALL经骨髓细胞学、细胞化学、免疫学表型、bcr-abl融合基因检测确诊为bcr-abl+ ALL（B细胞型）。初治时接受伊马替尼联合化疗诱导治疗，伊马替尼剂量为400 mg／d。完全缓解（CR）后8例接受allo-HSCT治疗，移植后bcr-abl融合基因转为阳性者给予伊马替尼（400～600 mg／d）治疗，3例接受伊马替尼与化疗交替巩固治疗。结果　11例获得CR，CR率91.7 %；诱导治疗2个疗程时bcr-abl融合基因转阴率为41.7 %；8例接受移植患者3例复发，3例化疗与伊马替尼交替巩固治疗的患者2例复发，伊马替尼联合造血干细胞移植组与伊马替尼联合化疗组患者的中位缓解期分别为16个月与10个月（P＜0.01）；中位生存期为18个月与12个月（P＜0.01）。结论　伊马替尼联合化疗诱导治疗bcr-abl+成年人ALL有较高的血液学和分子生物学缓解率，伊马替尼联合allo-HSCT的疗效优于伊马替尼联合化疗。

Imatinib combined with hematopoietic stem cell transplantation or chemotherapy for bcr-abl positive acute lymphoblastic leukemia

Objective To investigate the efficacy of imatinib combining with allogeneic hematopioetic stem cell transplantation or chemotherapy for bcr-abl positive acute lymphoblastic leukemia (ALL). Methods 12 cases were diagnosed on morphology, cytochemistry, immunophenotype and bcr-abl fusion gene. The induction is imatinib (400 mg/d) combining chemotherapy. 8 cases accepted allogeneic hematopoietic stem cell transplantation after complete remission (CR). If bcr-abl became positive, the patient was treated with imatinib (400～600 mg/d). 3 cases were tested with imatinib alternating chemotherapy after cr. Results 11 patients gained CR, CR rate 91.7 %; 5 patients (41.7 %) became bcr-abl negative through 2 courses induction. 3 cases relapsed after transplantation. 2 cases relapsed in imatinib combining chemotherapy group. The median remission interval is 16 months (imatinib combining transplantation group) and 10 months (imatinib combining chemotherapy group) (P <0.01) respectively. The median survival time is 18 months (imatinib combining transplantation group), and the other group (imatinib combining chemotherapy) is 12 months (P <0.01). Conclusion Imatinib combining chemotherapy achieved high CR rate for the bcr-abl positive ALL. Imatinib combining allogeneic hematopoietic stem cell transplantation is superior to imatinib combining chemotherapy for CR patients.